Several possible studies
Story checked
Upcoming forum will share patient perspectives on non-cystic fibrosis bronchiectasis care (opens in a new tab)
news-medical.net · 2026-10-14
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Upcoming forum will share patient perspectives on non-cystic fibrosis bronchiectasis care
news-medical.net · 2026-10-14
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedThe Bronchiectasis and NTM Association has announced plans for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting for non-cystic fibrosis bronchiectasis (NCFB).View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedThe meeting is modeled after the FDA's PFDD public meetings, and drug developers, FDA representatives, and other stakeholders will attend.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedNCFB is described as a chronic lung disease characterized by inflammation and chronic infection in which the airways become abnormally widened, thickened, and/or scarred.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedThe article says NCFB is now more widely recognized because awareness, research, and advances in imaging have improved understanding of the disease.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe first FDA-approved treatment for NCFB became available in 2025, but significant unmet needs remain, including delays in diagnosis, limited access to specialized care, and difficulty managing daily disease burden.View evidenceHide evidence
As statedfirst FDA-approved treatment in 2025
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedThe proposed NCFB EL-PFDD meeting is scheduled for late 2027 and will include a virtual element to improve accessibility.View evidenceHide evidence
As statedlate 2027
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe meeting is intended to enhance understanding of how living with NCFB affects daily life, capture diverse community perspectives, and inform regulatory decision-making and future therapy development.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Value-based pricing of brensocatib for frequently exacerbating non-cystic fibrosis bronchiectasis in China: a China-adapted, FEV1-inclusive time-dependent markov analysis.
Frontiers in Pharmacology · 2026 · PubMed
Importance of Understanding the Patient Experience in Healthcare: An Example of the Integrated Patient Journey in Non-Cystic Fibrosis Bronchiectasis (NCFB)
Medicon Medical Sciences · 2025 · Crossref
Evaluation of the methodology of independent Community Advisory Boards in health products research and development: a mixed-methods cross-sectional survey study.
2026 · Europe PMC
Evaluating the Efficacy of Brensocatib in Non-cystic Fibrosis Bronchiectasis.
Cureus · 2026 · PubMed
CFTR Modulator Therapy in an Adult Patient with Concurrent Cystic Fibrosis and Cerebral Palsy
B41. CASE REPORTS IN AIRWAY DISEASE, CYSTIC FIBROSIS, AND NON-CF BRONCHIECTASIS · 2022 · Crossref
And 10 more candidates considered.